and France, Germany, Italy, Spain, and the United Kingdom (“EU5”), with many more in other parts of the world. Thalassemia is an inherited blood disorder, affecting approximately 18,000-23,000 people in the U.S.
This agreement represents another significant milestone for CENTOGENE’s mission to enable the cure of 100 rare diseases within the next 10 years. By working with outstanding partners like CENTOGENE, we can together accelerate innovations that make a positive difference in patients’ lives.” “At Agios, we know that great science requires world-class teamwork. “As we look ahead to initiating three global, pivotal trials in thalassemia and sickle cell disease by the end of the year, we are pleased to expand our partnership with CENTOGENE to better understand the underlying genetics of patients in our studies and the potential impact of our investigational medicine,” said Sarah Gheuens, M.D., Ph.D., Chief Medical Officer at Agios.
Samples will be collected using CENTOGENE’s proprietary CentoCard® for dried blood spot analysis. Agios’ global clinical trials will enroll patients in North America, Europe, MENA, APAC, and LATAM. This collaboration will offer patients access to genetic testing to help identify causative mutations, including HBA1, HBA2, and HBB genes. Agios will be coordinating and bearing the costs for the programs further financial details were not disclosed. The Companies signed a commercial three-year fee-for-service agreement. Under a previous agreement, CENTOGENE provided support for Agios’ pyruvate kinase (“PK”) deficiency clinical program.
Under the terms of the new agreement, CENTOGENE will provide genetic testing and clinical trial support for Agios’ three global, pivotal trials in thalassemia and sickle cell disease. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced today that it has expanded its partnership with Agios Pharmaceuticals, Inc. 04, 2021 (GLOBE NEWSWIRE) - Centogene N.V. Providing Global Clinical Trial Support for Thalassemia and Sickle Cell Disease Will Deepen Understanding of Disease Characterization in the Search for a TreatmentĬAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, Nov.
0 kommentar(er)
